Clinical Trial Update: A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is planned to compare HLX17 with pembrolizumab (Keytruda) as first-line treatment in advanced non-squamous non-small cell lung cancer. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLX17
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING